TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00988806
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
Study: NCT00842335
Drug: JI-101
Normalized name: Ji Xue Cao Whole
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
Study: NCT00135824
Drug: Povidone K25 eye drops (povidone)
Normalized name: povidone K25
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00220896
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01725204
Drug: Dasatinib + PegIFN
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02170571
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00591916
Drug: Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
Study: NCT03023358
Drug: chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 30mg po twice a week
Study: NCT03023358
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4mg/m2 iv on day 1
Study: NCT03023358
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/d po on day 1-5
Study: NCT02601248
Drug: Theliatinib
Normalized name: Telatinib
DrugBank: Telatinib (DB15393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
Study: NCT00628108
Drug: Levocetirizine 1.25 mg
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
Study: NCT00740649
Drug: HSD-016
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02870907
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m²/d, IV (in the vein) from D1 to D5.
Study: NCT02870907
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1, 5 mg/m²/d, IV at D1.
Study: NCT02870907
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg/m²/d, IV from D1 to D5.
Study: NCT02870907
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,5 mg/m²/d, IV at D22 and D26
Study: NCT02870907
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 560 mg/m²/d, IV at D1.
Study: NCT02870907
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m²/d, IV from D1 to D5
Study: NCT02870907
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg/m²/d,IV from D1 to D5
Study: NCT02870907
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg, intrathecal Thiotepa injection at D1.
Study: NCT02870907
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,5 mg/m²/d), IV at D22
Study: NCT02870907
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC : 7/d, IV from D-8 to D-6.
Study: NCT02870907
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m²/d, IV from D -5 to D-3.
Study: NCT02870907
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg/m²/d, IV from D-5 to D-3.
Study: NCT03301207
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
Study: NCT03301207
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
Study: NCT03301207
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
Study: NCT00398476
Drug: fluticasone propionate (FP)
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 micrograms (mcg); an aqueous suspension of microfine FP
Study: NCT02802540
Drug: Nabilone
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
Study: NCT04324411
Drug: sirolimus and ATRA
Normalized name: ATRA
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
Study: NCT03703427
Drug: Vinorelbine Tartrate Oral
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2，d1；d8；q3w
Study: NCT00120497
Drug: somatropin (rDNA)
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml~Dosage regimen: 0.48 mg/kg/week~Route/rate of administration: subcutaneous injection, daily dose
Study: NCT00691886
Drug: dexmedetomidine hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
Study: NCT00253188
Drug: galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03024476
Drug: Pharmacological intensification based on olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Study drug will be provided from the roll-in period.~* Step I:~  * Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~ * Use olmesartan 40 mg if mean systolic blood pressure \>150 during the immediate past 2 days~* Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~* Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~* Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~* If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~* Use of beta-blockers is permitted if clinically indicated.~* At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule.
Study: NCT00398476
Drug: fluticasone furoate (FF)
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
Study: NCT03290131
Drug: Arbaclofen
Normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen Extended Release Tablet
Study: NCT00913874
Drug: Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
Normalized name: valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03788252
Drug: Renamezin
Normalized name: Cefamezin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 capsules once, three times a day, for 48 weeks
Study: NCT00913874
Drug: Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Normalized name: divalproex sodium 500 MG [Depakote]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00094146
Drug: Sandostatin LAR Depot
Normalized name: SandoSTATIN LAR Depot
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02513901
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
Study: NCT02926768
Drug: CK-101
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily
Study: NCT00882557
Drug: daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intradialytic: 9 mg/kg during the last 30 minutes of dialysis
Study: NCT00882557
Drug: daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/kg administered after a hemodialysis session
Study: NCT00680563
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sc every month (starting dose 1.2 micrograms/kg)
Study: NCT01543386
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
Study: NCT03075423
Drug: Ipilimumab plus nivolumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week
Study: NCT00576433
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000mg iv on days 1 and 15
Study: NCT00024414
Drug: DHA-paclitaxel
Normalized name: DHA-paclitaxel
DrugBank: Paclitaxel docosahexaenoic acid (DB05297)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02921269
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02484339
Drug: Radium-223 dichloride
Normalized name: radium-223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
Study: NCT01464437
Drug: AMG 151
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AMG 151 50 mg BID
Study: NCT01464437
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
Study: NCT03782142
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
Study: NCT02320734
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium given continuously to reach deep neuromuscular block
Study: NCT01464437
Drug: AMG 151
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AMG 151 100 mg BID
Study: NCT01464437
Drug: AMG 151
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AMG 151 200 mg BID
Study: NCT01464437
Drug: AMG 151
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AMG 151 100 mg QD
Study: NCT01464437
Drug: AMG 151
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AMG 151 200 mg QD
Study: NCT01464437
Drug: AMG 151
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AMG 151 400 mg QD
Study: NCT00460083
Drug: Elidel(R) (pimecrolimus 1%)
Normalized name: pimecrolimus Topical Cream [Elidel]
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03782142
Drug: Rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NNRTI
Study: NCT03782142
Drug: Prezcobix
Normalized name: Prezcobix
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PI
Study: NCT03782142
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: II
Study: NCT01159912
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate inhalation powder, 250 µg
Study: NCT01159912
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate inhalation powder, 100 µg
Study: NCT00225485
Drug: Effexor XR
Normalized name: Effexor XR
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00462995
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg once a day for 28 days
Study: NCT00462995
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
Study: NCT00943618
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
Study: NCT00943618
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
Study: NCT00566761
Drug: bevacizumab and triamcinolone
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
Study: NCT01147510
Drug: Combination of low ICS and montelukast
Normalized name: montelukast, combinations
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
Study: NCT01147510
Drug: Monotherapy of medium dose ICS
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
Study: NCT03359590
Drug: Sitagliptin 100 mg
Normalized name: SITagliptin 100 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.
Study: NCT02267343
Drug: ONO-4538
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03910244
Drug: Pomalidomide Oral Product
Normalized name: pomalidomide Oral Product
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific adverse event (AE) criteria.
Study: NCT03772158
Drug: Cetirizine 10mg
Normalized name: CETIRIZINE 10MG/ML INJ
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablet
Study: NCT03772158
Drug: Cetirizine 10 mg
Normalized name: cetirizine 10 MG
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate Release Tablet
Study: NCT02472080
Drug: gemcitabine -oxaliplatine combination
Normalized name: Oxaliplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
Study: NCT03620019
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
Study: NCT02156076
Drug: BMS-919373
Normalized name: BMS-919373
DrugBank: BMS-919373 (DB15047)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02156076
Drug: Placebo (Matching with BMS-919373)
Normalized name: BMS-919373
DrugBank: BMS-919373 (DB15047)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03620019
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
Study: NCT03620019
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
Study: NCT04288895
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
Study: NCT01101867
Drug: Aspart fixed dose
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed dose
Study: NCT01101867
Drug: Aspart flexible dose
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose based upon carbohydrate intake and total daily requirements
Study: NCT00072839
Drug: ALX-0600
Normalized name: ALX-009
DrugBank: ALX-009 (DB17916)
Approvals — FDA: no, EMA: no, PMDA: no
Description: teduglutide
Study: NCT00072839
Drug: teduglutide 0.05
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
Study: NCT00072839
Drug: teduglutide 0.2 mg
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.2 mg/kg/d subcutaneously injected into thigh or abdomen
Study: NCT00072839
Drug: Teduglutide 0.05 dose
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
Study: NCT00072839
Drug: teduglutide 0.1 mg dose
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
Study: NCT02327832
Drug: bone marrow-derived mesenchymal stem cells
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00608374
Drug: chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00608374
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00880919
Drug: quetiapine extended-release
Normalized name: Quetiapine Extended-Release Tablets
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Study: NCT00982007
Drug: Ferric Carboxymaltose (FCM)
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
Study: NCT00982007
Drug: Ferrous Sulfate Tablets
Normalized name: Ferrous Sulfate Tablets
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg Ferrous Sulfate tablets taken orally three times a day